Abstract 171P
Background
Atezo+Bev is recognized as the standard of care for systemic treatment-naïve uHCC pts. The key to prolonging survival is to manage vascular endothelial growth factor inhibitor-related adverse events while considering continued treatment. Proteinuria is the main adverse event leading to Bev interruption. However, the relationship between Bev-related proteinuria and renal dysfunction is unclear. Therefore, we retrospectively investigated the impact of proteinuria after starting Atezo+Bev on renal function in uHCC pts.
Methods
We performed a single-arm retrospective study of 100 uHCC pts treated with Atezo+Bev between Sep 25, 2020 and May 31, 2022, at Kindai University, Japan. The impact of proteinuria on renal function during Atezo+Bev treatment was analyzed in terms of the correlation between changes in urine protein creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR) relative to baseline.
Results
We analyzed 100 pts with data at baseline and at least twice after starting Atezo+Bev. The median age was 74 years (range 41‒89) and 75% were male. Performance status was 0–1 in 99% and 2 in 1%. Barcelona Clinic Liver Cancer stage was B in 62% and C in 38%. Child–Pugh class was A5, A6, in 61%, 29%. 60% had hypertension and 37% had diabetes mellitus. During the Atezo+Bev treatment period, the median (interquartile range) maximum increase from baseline in UPCR was 0.39 (0.08 to 2.05) and the median maximum decline from baseline in eGFR was −7.5 (−20.5 to −3.0) mL/min/1.73 m2. The Pearson and Spearman correlation coefficients (95% confidence interval) between the maximum UPCR increase and the maximum eGFR decline were −0.13 (−0.32 to 0.07) and −0.13 (−0.32 to 0.07), respectively.
Conclusions
The change in UPCR was not correlated with the change in eGFR during Atezo+Bev treatment. For safety concerns, Bev interruption criteria are set according to the degree of proteinuria, but we found that proteinuria does not necessarily impair renal function. Physicians should consider the risk-benefit profile when deciding whether to skip Bev in pts who develop proteinuria during treatment.
Clinical trial identification
UMIN000050692.
Editorial acknowledgement
Medical writing support was provided by Nicholas D. Smith (EMC K.K.), and funded by Chugai Pharmaceutical Co., Ltd.
Legal entity responsible for the study
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine.
Funding
Chugai Pharmaceutical Co., Ltd.
Disclosure
K. Ueshima: Financial Interests, Personal, Invited Speaker, Concurrent roles with an advisory board: Chugai, Eisai, Takeda, Lilly Japan; Financial Interests, Personal, Invited Speaker: AstraZeneca, Otsuka, Taiho, Sumitomo, MSD, Kowa, EA pharma, AbbVie, Aska; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Local PI: Chugai. M. Kudo: Financial Interests, Personal, Invited Speaker: Eisai, Chugai, Eli Liiy, Bayer, Takeda, AstraZeneca; Financial Interests, Institutional, Research Grant: Otsuka, EA Pharma, Taiho, Eisai, AbbVie, GE Healthcare, Chugai. All other authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract